Vaccines

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

The acquisition, advised by Westcove Partners, highlights the trend of private equity-fueled consolidation aimed at enhancing clinical trial access.

Dexcel Pharma USA acquires Zubsolv®, a key opioid addiction therapy, signaling a major strategic shift into the branded drug market in the U.S.

Sana Biotechnology prepares for its pivotal J.P. Morgan update, balancing groundbreaking diabetes data against a ticking financial clock and fierce competition.

Employer health plans are using 'alternative funding' to cut costs, but critics warn these schemes force patients to use risky, non-FDA approved drugs.

A biotech firm's promising concussion therapy, backed by NFL's Alex Smith, shows an 85% responder rate and now seeks public funding for its final push.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

Kelonia Therapeutics gets the FDA green light to expand trials for its in vivo CAR-T therapy, a single-infusion treatment that could redefine cancer care.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.

With seasoned executive Adam Rosenberg at the helm, AstronauTx is advancing its novel sleep-focused therapy, backed by major investors, into the Alzheimer's arena.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

The first-ever Wegovy pill is here. Digital health firm eMed is partnering with Novo Nordisk to offer it, promising a new era of guided, responsible care.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.